Flebogamma DIF 50 mg/ml solution for infusion

DRUG2 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Novartis Pharma AG

Conditions

Treatment-resistant generalized Myasthenia Gravisanti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)

Phase 1

An open-label, multi-center, phase I/II study to assess safety, efficacy, and cellular kinetics of YTB323 in participants with treatment-resistant generalized myasthenia gravis

RecruitingCTIS2024-513589-20-00

Novartis Pharma AGTreatment-resistant generalized Myasthenia Gravis

Start: 2025-07-29Target: 3Updated: 2026-01-07

Phase 2

A PHASE-2B, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE ACTIVITY AND SAFETY OF INEBILIZUMAB IN ANTI-NMDA RECEPTOR ENCEPHALITIS AND ASSESS MARKERS OF DISEASE (EXTINGUISH)

RecruitingCTIS2023-504686-23-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)

Start: 2024-12-10Target: 26Updated: 2025-11-13